CCSG Developmental Funds provide a key source of support for the strategic and programmatic priorities and scientific opportunities of Wake Forest Baptist Comprehensive Cancer Center (WFBCCC), as identified through Planning and Evaluation processes. These funds provide opportunities to explore innovative pilot projects, new collaborations, and new technologies. In the current funding period, Developmental Funds have been used for the purposes of 1) pilot funds and 2) Shared Resource development. The WFBCCC proposes to continue funding in these two categories in the next funding cycle. It will also fund one Research Staff Investigator with Developmental Funds, in accordance with the new CCSG guidelines. Previously, Research Staff Investigators were supported by a separate CCSG budget category, not as a part of Developmental Funds. Using CCSG Developmental Funds, the WFBCCC supported 21 pilot projects in the amount of $657,900 between 2011 and 2015. The WFBCCC realized a 13.5 fold return on investment for CCSG-supported pilots, excluding the pilots from 2015, which have not yet had time to yield a return.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA012197-46
Application #
10092982
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-02-01
Project End
2022-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
46
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Sirkisoon, Sherona R; Carpenter, Richard L; Rimkus, Tadas et al. (2018) Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. Oncogene 37:2502-2514
Goyal, Amrita; Carter, Joi B; Pashtan, Itai et al. (2018) Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: A retrospective study. J Am Acad Dermatol 78:408-410
Su, Weijun; Hong, Lixin; Xu, Xin et al. (2018) miR-30 disrupts senescence and promotes cancer by targeting both p16INK4A and DNA damage pathways. Oncogene 37:5618-5632
Miller Jr, David P; Denizard-Thompson, Nancy; Weaver, Kathryn E et al. (2018) Effect of a Digital Health Intervention on Receipt of Colorectal Cancer Screening in Vulnerable Patients: A Randomized Controlled Trial. Ann Intern Med 168:550-557
Rimkus, Tadas K; Carpenter, Richard L; Sirkisoon, Sherona et al. (2018) Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44. Cancer Res 78:2589-2600
Bonin, Keith; Smelser, Amanda; Moreno, Naike Salvador et al. (2018) Structured illumination to spatially map chromatin motions. J Biomed Opt 23:1-8
Rogers, LeAnn C; Davis, Ryan R; Said, Naveen et al. (2018) Blocking LPA-dependent signaling increases ovarian cancer cell death in response to chemotherapy. Redox Biol 15:380-386
Maggiore, Ronald J; Callahan, Kathryn E; Tooze, Janet A et al. (2018) Geriatrics fellowship training and the role of geriatricians in older adult cancer care: A survey of geriatrics fellowship directors. Gerontol Geriatr Educ 39:170-182
Melvin, Ryan L; Xiao, Jiajie; Godwin, Ryan C et al. (2018) Visualizing correlated motion with HDBSCAN clustering. Protein Sci 27:62-75
Faig, Jennifer; Haughton, Michael; Taylor, Richard C et al. (2018) Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy. Am J Clin Oncol 41:432-440

Showing the most recent 10 out of 548 publications